Marksans Pharma Limited

NSEI:MARKSANS Voorraadrapport

Marktkapitalisatie: ₹130.0b

Marksans Pharma Inkomsten in het verleden

Verleden criteriumcontroles 5/6

Marksans Pharma has been growing earnings at an average annual rate of 21.2%, while the Pharmaceuticals industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 15.9% per year. Marksans Pharma's return on equity is 16%, and it has net margins of 14.7%.

Belangrijke informatie

21.2%

Groei van de winst

19.3%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie17.5%
Inkomstengroei15.9%
Rendement op eigen vermogen16.0%
Nettomarge14.7%
Volgende winstupdate12 Nov 2024

Recente prestatie-updates uit het verleden

Solid Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

Jun 07
Solid Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

Recent updates

Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?

Oct 24
Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?

Optimistic Investors Push Marksans Pharma Limited (NSE:MARKSANS) Shares Up 45% But Growth Is Lacking

Sep 21
Optimistic Investors Push Marksans Pharma Limited (NSE:MARKSANS) Shares Up 45% But Growth Is Lacking

Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 26% But Many Are Still Ignoring The Company

Jul 28
Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 26% But Many Are Still Ignoring The Company

Solid Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

Jun 07
Solid Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?

May 31
Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?

Sentiment Still Eluding Marksans Pharma Limited (NSE:MARKSANS)

Feb 16
Sentiment Still Eluding Marksans Pharma Limited (NSE:MARKSANS)

Here's Why Marksans Pharma (NSE:MARKSANS) Has Caught The Eye Of Investors

Jan 26
Here's Why Marksans Pharma (NSE:MARKSANS) Has Caught The Eye Of Investors

We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease

Dec 02
We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease

Marksans Pharma (NSE:MARKSANS) Seems To Use Debt Quite Sensibly

Jun 21
Marksans Pharma (NSE:MARKSANS) Seems To Use Debt Quite Sensibly

Robust Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

Nov 17
Robust Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

This Is The Reason Why We Think Marksans Pharma Limited's (NSE:MARKSANS) CEO Deserves A Bump Up To Their Compensation

Sep 16
This Is The Reason Why We Think Marksans Pharma Limited's (NSE:MARKSANS) CEO Deserves A Bump Up To Their Compensation

Marksans Pharma (NSE:MARKSANS) Is Increasing Its Dividend To ₹0.25

Sep 01
Marksans Pharma (NSE:MARKSANS) Is Increasing Its Dividend To ₹0.25

Marksans Pharma (NSE:MARKSANS) Could Easily Take On More Debt

Jun 14
Marksans Pharma (NSE:MARKSANS) Could Easily Take On More Debt

Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?

May 27
Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?

Is Marksans Pharma (NSE:MARKSANS) A Risky Investment?

Feb 19
Is Marksans Pharma (NSE:MARKSANS) A Risky Investment?

Marksans Pharma Limited's (NSE:MARKSANS) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Feb 04
Marksans Pharma Limited's (NSE:MARKSANS) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Here's Why We Think Marksans Pharma (NSE:MARKSANS) Is Well Worth Watching

Jan 20
Here's Why We Think Marksans Pharma (NSE:MARKSANS) Is Well Worth Watching

Do Institutions Own Marksans Pharma Limited (NSE:MARKSANS) Shares?

Jan 05
Do Institutions Own Marksans Pharma Limited (NSE:MARKSANS) Shares?

Shareholders Are Thrilled That The Marksans Pharma (NSE:MARKSANS) Share Price Increased 250%

Dec 21
Shareholders Are Thrilled That The Marksans Pharma (NSE:MARKSANS) Share Price Increased 250%

What Can We Conclude About Marksans Pharma's (NSE:MARKSANS) CEO Pay?

Dec 06
What Can We Conclude About Marksans Pharma's (NSE:MARKSANS) CEO Pay?

These 4 Measures Indicate That Marksans Pharma (NSE:MARKSANS) Is Using Debt Safely

Nov 19
These 4 Measures Indicate That Marksans Pharma (NSE:MARKSANS) Is Using Debt Safely

Opbrengsten en kosten

Hoe Marksans Pharma geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

NSEI:MARKSANS Opbrengsten, kosten en inkomsten (INR Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Jun 2422,6803,3383,0590
31 Mar 2421,7743,1373,0590
31 Dec 2321,0343,1642,8750
30 Sep 2319,9712,9652,7520
30 Jun 2319,1842,7432,6370
31 Mar 2318,5212,6632,5230
31 Dec 2217,8422,1232,4360
30 Sep 2216,6702,0042,3750
30 Jun 2215,7561,8472,3260
31 Mar 2214,9081,8682,2500
31 Dec 2114,0692,3672,3510
30 Sep 2114,0262,4732,2690
30 Jun 2114,0642,5182,0370
31 Mar 2113,7622,3852,0960
31 Dec 2013,8172,0181,9080
30 Sep 2013,1421,7241,8330
30 Jun 2012,2031,4761,7000
31 Mar 2011,3441,2081,7850
31 Dec 1910,4638791,7190
30 Sep 199,9728341,6770
30 Jun 1910,0997801,6310
31 Mar 1910,0018041,6590
31 Dec 189,5236661,6010
30 Sep 189,2235821,5990
30 Jun 189,2724631,4740
31 Mar 189,1273581,5340
31 Dec 178,9183431,5280
30 Sep 178,9492751,5500
30 Jun 178,0151871,4920
31 Mar 177,6721131,5470
31 Dec 167,926701,4750
30 Sep 167,9481361,4580
30 Jun 168,6994811,4240
31 Mar 168,9337851,2700
31 Dec 158,5361,0931,5850
30 Sep 158,4951,1911,3970
30 Jun 158,0451,1547280
31 Mar 157,9671,0947580
31 Dec 147,8509501,4820
30 Sep 147,4058971,1210
30 Jun 146,9147866930
31 Mar 146,3007191,0910
31 Dec 135,9501,0201,0130

Kwaliteitswinsten: MARKSANS has high quality earnings.

Groeiende winstmarge: MARKSANS's current net profit margins (14.7%) are higher than last year (14.3%).


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: MARKSANS's earnings have grown significantly by 21.2% per year over the past 5 years.

Versnelling van de groei: MARKSANS's earnings growth over the past year (21.7%) exceeds its 5-year average (21.2% per year).

Winst versus industrie: MARKSANS earnings growth over the past year (21.7%) exceeded the Pharmaceuticals industry 19.1%.


Rendement op eigen vermogen

Hoge ROE: MARKSANS's Return on Equity (16%) is considered low.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden